Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- THE ROSEN LAW FIRM, P. A.AARD Deadline: AARD Investors with Losses in Excess of $100K Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud LawsuitWhy: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration...
- PTC Therapeutics, Inc.PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy– Completion of BLA submission expected in Q4 2026 – — PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time...
- Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor ConferenceCadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, announced that CEO Quang X. Pham will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.
- Travere Therapeutics, Inc.Travere Therapeutics Announces Planned Chief Executive Officer TransitionSAN DIEGO, September 21, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Company’s Board of Directors has unanimously appointed Bradley L.
- Kaplan Fox & Kilsheimer LLPKaplan Fox Reminds Investors of a Deadline for a Securities Fraud Class Action Lawsuit Against ARS Pharmaceuticals Inc. (SPRY) on October 5, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in ARS and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox...
- Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitGlancy Prongay Wolke & Rotter LLP reminds investors of the upcoming November 2, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026 inclusive (the “Class Period”).
- Alzinova Advances Dual Approach to Alzheimer’s Treatment and Diagnosis as World Alzheimer’s Day Highlights Unmet NeedOn World Alzheimer’s Day, Swedish biotech Alzinova highlights progress in Alzheimer’s treatment and diagnostics as ALZ-101 enters Phase II start-up.
- MaaT Pharma Announces Upcoming Pre-IND Meeting with the FDA and Advances MaaT034 Toward Clinical Development in Solid TumorsLYON, France, September 21, 2026--MaaT Pharma Announces Upcoming Pre-IND Meeting with the FDA and Advances MaaT034 Toward Clinical Development in Solid Tumors
- Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)Company announcement No. 49 / 2026
- Leads Biolabs’ Pivotal Phase IIb Study of Opamtistomig (LBL-024) in Advanced EP-NEC Selected as ESMO 2026 Late-Breaking Abstract; Three Studies Selected for Proffered Paper PresentationsLeads Biolabs’ Pivotal Phase IIb Study of Opamtistomig (LBL-024) in Advanced EP-NEC Selected as ESMO 2026 Late-Breaking Abstract;
- Quest DiagnosticsNearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest DiagnosticsCompanies: Quest DiagnosticsStudy published in JAMA Network Open of over 193,000 patients nationwide reveals that individuals with evidence of exposure to Borrelia burgdorferi, the bacterium that causes Lyme disease, are more than four times as likely to have antibodies against other tick-borne pathogens compared to...
- Serbian Biotech Startup Takes Its Journey from Belgrade to Cambridge with Documentary on Longevity ScienceBELGRADE, Serbia, September 21, 2026--BioEridan, a Serbian biotechnology startup backed by Telekom Srbija Group’s TS Ventures Fund, has premiered a new documentary showcasing its development of underwater Aquafarms and its ambition to contribute to the next generation of longevity science.